Overseas expansion brings award for diagnostic company
21 May 2018 by Evoluted New Media
Molecular diagnostics company, Elucigene Diagnostics, has been awarded the Queen’s Award for Enterprise for success in international trade.
Elucigene’s products are used for the rapid detection of genetic diseases such as the cystic fibrosis, in which the company is the market leader in Europe. More than 80% of Elucigene’s annual sales of £3.7 million come from exports. The company, which has grown from five to 30 employees over the past four years, and has demonstrated substantial growth in overseas earnings and in commercial success during the same period.
Chief executive Dr Mark Street-Docherty said: “We are thrilled to have won this most prestigious of awards. Taking a UK-only approach to our sales would not have delivered the strong growth we wanted to see and it is great to be flying the flag for UK life sciences in so many international markets. Winning the Queen’s Award has been a tremendous team effort and it is a wonderful vote of confidence in our business as we look forward to the next phase of our growth strategy.”
The company is based at the Citylabs 1.0 biomedical campus in Manchester and is part of the city’s growing precision and personalised medicine sector, developing, manufacturing and distributing a suite of innovative diagnostic products to more than 50 countries around the world.
